174
Views
14
CrossRef citations to date
0
Altmetric
Drug Profile

Telmisartan for the reduction of cardiovascular morbidity and mortality

, , , &
Pages 151-161 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sverre Kjeldsen, Giuseppe Mancia, Roland Schmieder, Michaela Mattheus & Thomas Unger. (2013) An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. Expert Review of Cardiovascular Therapy 11:6, pages 673-682.
Read now
LM Ruilope & Helmut Schumacher. (2012) Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension. Expert Opinion on Pharmacotherapy 13:16, pages 2417-2425.
Read now

Articles from other publishers (12)

Robert Krysiak, Marcin Basiak, Witold Szkróbka & Bogusław Okopień. (2021) The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome. The Journal of Clinical Pharmacology 61:9, pages 1165-1173.
Crossref
Leidyanne Ferreira Gonçalves & Caroline Fernandes‐Santos. (2020) Telmisartan detection by UV spectrophotometry in mice drinking water. Analytical Science Advances 2:7-8, pages 408-415.
Crossref
Khuraijam Dhanachandra Singh & Sadashiva S. Karnik. (2020) Angiotensin Type 1 Receptor Blockers in Heart Failure. Current Drug Targets 21:2, pages 125-131.
Crossref
Maisie M. Barbosa, Aurigena A. de Araújo, Raimundo F. de Araújo Júnior, Gerlane C. B. Guerra, Gerly A. de Castro Brito, Renata C. Leitão, Susana B. Ribeiro, Emanuella de Aragão Tavares, Roseane C. Vasconcelos, Vinícius B. Garcia & Caroline A. C. X. de Medeiros. (2018) Telmisartan Modulates the Oral Mucositis Induced by 5-Fluorouracil in Hamsters. Frontiers in Physiology 9.
Crossref
Somasundaram Arumugam, Remya Sreedhar, Rajarajan A. Thandavarayan, Vengadeshprabhu Karuppagounder, Prasanna Krishnamurthy, Kenji Suzuki, Masahiko Nakamura & Kenichi Watanabe. (2016) Angiotensin receptor blockers: Focus on cardiac and renal injury. Trends in Cardiovascular Medicine 26:3, pages 221-228.
Crossref
Ahmed H.H. Bakheit, Ahmed A. Abd-Elgalil, Bakheit Mustafa, Anzarul Haque & Tanveer A. Wani. 2015. 371 429 .
Gregg Lanier, Kedar Sankholkar & Wilbert S. Aronow. (2014) Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin–Angiotensin–Aldosterone System Antagonists. American Journal of Therapeutics 21:5, pages 419-435.
Crossref
A. Nenicu, C. Korbel, Y. Gu, M. D. Menger & M. W. Laschke. (2014) Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-  by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. Human Reproduction 29:5, pages 1011-1024.
Crossref
T. Kishi, Y. Hirooka & K. Sunagawa. (2013) Telmisartan Reduces Mortality and Left Ventricular Hypertrophy With Sympathoinhibition in Rats with Hypertension and Heart Failure. American Journal of Hypertension 27:2, pages 260-267.
Crossref
Harold Bays, Pingjin Gao, Birgit Völker, Michaela Mattheus, Luis M. Ruilope & Dingliang Zhu. (2013) Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. International Journal of Hypertension 2013, pages 1-13.
Crossref
Ahmed H. Mitwalli, Ahmed Al Harthi, Hussam Mitwalli, Ayman Al Juwayed, Noura Al Turaif & Mohammed A. Mitwalli. (2013) Awareness, attitude, and distribution of high blood pressure among health professionals. Journal of the Saudi Heart Association 25:1, pages 19-24.
Crossref
Paolo Verdecchia, Giorgio Gentile, Fabio Angeli & Gianpaolo Reboldi. (2012) Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin–angiotensin system blockers. Therapeutic Advances in Cardiovascular Disease 6:2, pages 81-91.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.